Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

被引:0
|
作者
Edward Sausville
Patricia LoRusso
Michael Carducci
Judith Carter
Mary F. Quinn
Lisa Malburg
Nilofer Azad
David Cosgrove
Richard Knight
Peter Barker
Sonya Zabludoff
Felix Agbo
Patricia Oakes
Adrian Senderowicz
机构
[1] University of Maryland,Marlene and Stewart Greenebaum Cancer Center
[2] Wayne State University School of Medicine,Karmanos Cancer Center
[3] Johns Hopkins Medical Institutions,Sidney Kimmel Comprehensive Cancer Center
[4] AstraZeneca,undefined
来源
关键词
AZD7762; Chk1; Solid tumors; Phase I; Safety; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:539 / 549
页数:10
相关论文
共 50 条
  • [21] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [22] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [23] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [24] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [25] A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)
    Dillon, Magnus T.
    Espinasse, Aude
    Ellis, Sally
    Mohammed, Kabir
    Grove, Lorna G.
    McLellan, Lyndall
    Smith, Simon A.
    Ross, Graham
    Adeleke, Sola
    Woo, Kin
    Josephides, Eleni
    Spicer, James F.
    Forster, Martin D.
    Harrington, Kevin J.
    CANCER RESEARCH, 2017, 77
  • [26] A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Ullenhag, Gustav J.
    Rossmann, Eva
    Liljefors, Maria
    PLOS ONE, 2015, 10 (04):
  • [27] A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors
    Mavroudis, D
    Pappas, P
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Vardakis, N
    Nikolaidou, M
    Samonis, G
    Marselos, M
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 304 - 312
  • [28] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [29] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [30] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470